Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?

Mark Levis

doi:10.1016/j.beha.2021.101246

Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?

Mark Levis

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

It is often assumed that all patients with FLT3 (FMS-Like Tyrosine kinase-3)-mutated AML who undergo an allogeneic transplant should receive maintenance therapy with a FLT3 inhibitor. The validity of this assumption is controversial.

Original language	English (US)
Article number	101246
Journal	Best Practice and Research: Clinical Haematology
Volume	34
Issue number	1
DOIs	https://doi.org/10.1016/j.beha.2021.101246
State	Published - Mar 2021

Keywords

AML
Allogeneic transplant
FLT3
Tyrosine kinase inhibitor

ASJC Scopus subject areas

Oncology
Clinical Biochemistry

Access to Document

10.1016/j.beha.2021.101246

Cite this

@article{c73a2bd7ce524ea5b9c5b6cd997e22cf,

title = "Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?",

abstract = "It is often assumed that all patients with FLT3 (FMS-Like Tyrosine kinase-3)-mutated AML who undergo an allogeneic transplant should receive maintenance therapy with a FLT3 inhibitor. The validity of this assumption is controversial.",

keywords = "AML, Allogeneic transplant, FLT3, Tyrosine kinase inhibitor",

author = "Mark Levis",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = mar,

doi = "10.1016/j.beha.2021.101246",

language = "English (US)",

volume = "34",

journal = "Best Practice and Research: Clinical Haematology",

issn = "1521-6926",